Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new pill take on brain cancer?

NCT ID NCT07739017

Disease control Sponsor: Olivia Newton-John Cancer Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This early-stage trial tests an experimental drug called CT-179 in people with glioblastoma, an aggressive brain cancer. The study has two parts: one for patients whose cancer has returned, and another for newly diagnosed patients who will also receive radiation therapy. The main goal is to find the safest dose and understand how the drug behaves in the body, paving the way for larger studies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CT-179
What this could lead to
If successful, this could lead to a new treatment option for glioblastoma, a type of brain cancer with limited therapies.
What could go wrong
This is an early-phase trial, so the drug may not be effective or may cause unexpected side effects. The results will only establish a safe dose, not prove benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 54 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female aged ≥ 18 years at the time of signing informed consent * Supratentorial, histologically confirmed diagnosis of primary GBM that meets the current diagnostic classification: 2021 WHO Classification of Tumors of the Central Nervous System * KPS score ≥ 70 * Adequate organ function * Contraception during study participation, as applicable * Able to swallow tablets Exclusion Criteria: * Treatment with an investigational agent within the last 30 days excluding 5- aminolevulinic acid (5-ALA) * Placement of Gliadel wafers or similar local therapy at time of surgery * Receive bevacizumab * Evidence of intracranial or intra-tumoral hemorrhage * Significant concomitant disorder or serious intercurrent illness * History of prior malignancy, except adequately treated non-melanoma skin cancer, carcinoma in-situ of the cervix, or disease-free for more than 5 years * Treatment for HIV, hepatitis B, or hepatitis C * Any gastrointestinal disorder that could result in reduced absorption of CT-179 * Any psychiatric illness or social situation that would limit compliance with study requirements * Dose of dexamethasone higher than 4 mg/day within 1 week of the first dose of study medication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Newly diagnosed MGMT unmethylated glioblastoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer glioblastoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Newly diagnosed MGMT unmethylated glioblastoma Recurrent glioblastoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Austin Health

    Heidelberg, Victoria, 3084, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, 4006, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.